Oncorus, Inc. (NASDAQ:ONCR) was founded in 2015 and is headquartered in Cambridge, Massachusetts, with 40 full-time employees. It is a clinical-stage biopharmaceutical company dedicated to the development of next-generation viral immunotherapy to change the treatment effect of cancer patients .
Oncorus, Inc. (ONCR):
Oncorus is a biopharmaceutical company dedicated to the development of next-generation viral immunotherapies to change the treatment of cancer patients.
Although immunotherapy has improved the therapeutic effect of some patients, unfortunately, many patients do not meet or do not respond to existing immunotherapy. Oncorus’ goal is to enable more patients to cope with this revolutionary method of using the human immune system to fight cancer.
Based on Oncorus’ oncolytic Herpes Simplex Virus (oHSV) platform and synthetic virus platform, the company is advancing intra-tumor and intravenous drug product candidates for multiple indications and requiring a large number of indications. Oncorus’ viral immunotherapy aims to selectively attack and kill tumor cells, and deliver transgenes to stimulate multiple branches of the immune system to fight tumors.
Oncorus product line
Oncorus, Inc. (ONCR) financing:
- On July 19, 2016, on the Series A financing, Oncorus, Inc. received MPM Capital’s lead investment, and Deerfield, Celgene , Arkin Bio Ventures, Excelyrate Capital and other 6 institutions participated in the investment of 57 million US dollars.
- On December 16, 2016, on the A+ round of financing, Oncorus, Inc. received an exclusive £4 million investment from Astellas Venture Management.
- On August 21, 2019, Oncorus, Inc. received funding from Cowen Healthcare Investments and Perceptive Advisors in the B round of financing, and 13 institutions including MPM Capital, Celgene, Astellas Venture Management, and Surveyor Capital participated in the investment of $79.5 million.
Oncorus, Inc. (ONCR) investment:
Oncorus, Inc. (NASDAQ:ONCR) listed on NASDAQ on 10/2/2020 IPO, the issue price is $15.00, 5.8 million shares are issued, 87 million US dollars are raised, underwriting by Jefferies/Evercore ISI/Piper Sandler.